Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable ( MSS) colorectal cancer (CRC)

被引：0
|
作者：
Christenson, Eric S.
Wala, Jeremiah A.
Parkinson, Rose
Collins, Natalie B.
Jakubowski, Christopher
Lin, Jea-Ren
Wang, Hao
Ho, Won Jin
Chan, Sabrina
Klein, Rachel
Cetasaan, Yvette
Johnson, Emma
Berg, Maureen
Meyerhardt, Jeffrey
Schlechter, Benjamin
Singh, Harshabad
Sorger, Peter K.
Giannakis, Marios
Azad, Nilofer
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT007
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase II study of cabozantinib and nivolumab in refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC).
    Leal, Alexis Diane
    Blatchford, Patrick Jud
    Kim, Sunnie S.
    Lentz, Robert William
    Kemme, Douglas Jerome
    Russen, McKenna
    Friedrich, Tyler
    Mathew, Lynn
    Hoyer, Robert John
    Kono, Scott Arthur
    Baiyee Toegel, Emily
    Bagby, Stacey M.
    Dominguez, Adrian
    Davis, S. Lindsey
    Pitts, Todd
    Lieu, Christopher Hanyoung
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 229 - 229
  • [2] A phase 2 study evaluating response and biomarkers in patients with microsatellite stable (MSS) advanced colorectal cancer (CRC) treated with nivolumab/relatlimab
    Christenson, Eric
    Durham, Jennifer N.
    Brancati, Madelena
    Bruning, Heather Davis
    Petrie, Susan
    Wang, Hao
    Lu, Jiayun
    Bever, Katherine M.
    Laheru, Dan
    De Jesus-Acosta, Ana
    Donehower, Ross C.
    Pishvaian, Michael J.
    Azad, Nilofer Saba
    Zhu, Qingfeng
    Llosa, Nicolas Jose
    Housseau, Franck
    Anders, Robert
    Pardoll, Drew M.
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC).
    Yu, James
    Kim, Youngchul
    Mehta, Rutika
    Miao, Ruoyu
    Strosberg, Jonathan R.
    Imanirad, Iman
    Kim, Dae Won
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 188 - 188
  • [4] Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
    Fakih, Marwan
    Raghav, Kanwal Pratap Singh
    Chang, David Z.
    Bendell, Johanna C.
    Larson, Timothy
    Cohn, Allen Lee
    Huyck, Timothy K.
    Cosgrove, David
    Fiorillo, Joseph A.
    Garbo, Lawrence E.
    Ravimohan, Shruthi
    Potter, Von
    D'Adamo, David
    Sharma, Neelesh
    Wang, Ying A.
    Coppieters, Sabine
    Herpers, Matthias
    de Oliveira, Carolina Soares Viana
    Paulson, Andrew Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Kopetz, Scott
    Hwang, Hyunsoo
    Yuan, Ying
    DePinho, Ronald Anthony
    Zebala, John
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Correlative analysis of metformin and nivolumab combination in treatment-refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Farran, Batoul
    Switchenko, Jeffrey M.
    Khalil, Lana
    Shaib, Walid L.
    Olson, Brian
    Ruggieri, Amanda
    Wu, Christina
    Alese, Olatunji B.
    Diab, Maria
    Lesinski, Gregory B.
    El-Rayes, Bassel
    Akce, Mehmet
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Microsatellite-Stable Colorectal Cancer (MSS CRC) Shows Enrichment for Loss of Neoantigenic Mutations (NAMs) Compared to CRC with Microsatellite Instability (MSI)
    Nadhamuni, V. Srirangam
    Lakatos, E.
    Househam, J.
    Heide, T.
    Cresswell, G.
    Spiteri, I.
    Mossner, M.
    Kimberley, C.
    Ortiz, L. Zapata
    James, C.
    Lynn, C.
    Berner, A.
    Costa, H.
    Mitchinson, M.
    Jansen, M.
    Caravagna, G.
    Rodriguez-Justo, M.
    Shibata, D.
    Bridgewater, J.
    Baker, A-M
    Sottoriva, A.
    Graham, T.
    JOURNAL OF PATHOLOGY, 2021, 255 : S33 - S33
  • [8] Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.
    Morris, Van K.
    Parseghian, Christine Megerdichian
    Escano, Michelle
    Johnson, Benny
    Raghav, Kanwal Pratap Singh
    Dasari, Arvind
    Huey, Ryan
    Overman, Michael J.
    Willis, Jason
    Lee, Michael Sangmin
    Wolff, Robert A.
    Kee, Bryan K.
    Le, Phat
    Margain, Cori
    Gallup, Dave
    Tam, Alda
    Foo, Wai Chin
    Xiao, Lianchun
    Yun, Kyuson
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
    Parikh, Aparna Raj
    Clark, Jeffrey William
    Wo, Jennifer Yon-Li
    Yeap, Beow Y.
    Allen, Jill N.
    Blaszkowsky, Lawrence Scott
    Ryan, David P.
    Giantonio, Bruce J.
    Weekes, Colin D.
    Zhu, Andrew X.
    Van Seventer, Emily E.
    Matlack, Lauren
    Foreman, Bronwen
    Ly, Leilana
    Drapek, Lorraine C.
    Ting, David Tsai
    Corcoran, Ryan Bruce
    Hong, Theodore S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)
    Lemech, Charlotte
    Dredge, Keith
    Bampton, Darryn
    Hammond, Edward
    Clouson, Andrew
    Waterhouse, Nigel
    Stanley, Amanda
    Leveque-ElMouttie, Lucie
    Chojnowski, Grace
    Haydon, Andrew
    Pavlakis, Nick
    Burge, Matthew
    Brown, Michael
    Goldstein, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A367 - A367
12345